Skip to main content
Amandeep Godara
Rating: 4.9 of 5
( out of 244 reviews )

Amandeep Godara, MBBS

Languages spoken: Hindi, English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
  • Dr. Amandeep Godara is an Associate Professor with the Division of Hematology & Hematologic Malignancies. He completed his Hematology-Oncology fellowship at Tufts Medical Center with a clinical and research interest in plasma cell disorders. His research focuses on developing new therapeutic targets and tools for assessment of treatment response in Multiple Myeloma, Amyloidosis and other monoclonal gammopathies. His work has been presented at national and international scientific meetings. He was a recipient of the Amyloidosis Foundation David Seldin, MD, PhD Memorial Research Grant. He also received training in blood and marrow transplantation at Stanford University. He completed his medical school at Government Medical College, Aurangabad, India and his internal medicine residency at Wayne State University. Dr. Godara treats patients with Multiple Myeloma, Amyloidosis, Waldenström's Macroglobulinemia, and other plasma cell disorders.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine (Sub: Hematology)

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 244 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very pleasant and knowledgeable. made me feel as if he really cared about me and taking care of all my needs!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Godara is competent, caring, empathetic and professional. He is a delight to work with.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Outstanding professionalism, knowledge and listened to comments and questions - explaining in great detail current medical conditions and treatment options. An excellent gentleman and Doctor!!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Kind, efficient, knowledgeable, humorous, very good at explaining my treatments and progress along with my future prognosis. Highly recommend him as your doctor

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Godara is amazing! He is professional, competent, kind, and understanding.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Godara is terrific. He is competent, compassionate, and professional.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Appreciate his care and concern.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He was very helpful in explaining things, so we could understand them better. Very respectful and friendly.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He's doing wonders

  • Dr. Amandeep Godara is an Associate Professor with the Division of Hematology & Hematologic Malignancies. He completed his Hematology-Oncology fellowship at Tufts Medical Center with a clinical and research interest in plasma cell disorders. His research focuses on developing new therapeutic targets and tools for assessment of treatment response in Multiple Myeloma, Amyloidosis and other monoclonal gammopathies. His work has been presented at national and international scientific meetings. He was a recipient of the Amyloidosis Foundation David Seldin, MD, PhD Memorial Research Grant. He also received training in blood and marrow transplantation at Stanford University. He completed his medical school at Government Medical College, Aurangabad, India and his internal medicine residency at Wayne State University. Dr. Godara treats patients with Multiple Myeloma, Amyloidosis, Waldenström's Macroglobulinemia, and other plasma cell disorders.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine (Sub: Hematology)

    Education history

    Professional Medical Medicine - Government Medical College M.B.B.S.
    Internship Internal Medicine - Wayne State University School of Medicine Intern
    Residency Internal Medicine - Wayne State University School of Medicine Resident
    Fellowship Bone Marrow Transplantation and Immunotherapy - Stanford University School of Medicine Fellow
    Fellowship Hematology-Oncology - Tufts Medical Center Fellow

    Selected Publications

    Journal Article

    1. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger (2021). Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. Clinical neurology and neurosurgery, 206, 106708. (Read full publication)
    2. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski A (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942. (Read full publication)
    3. Godara A, Palladini (2020). Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis. Hematology/oncology clinics of North America, 34(6), 1145-1159. (Read full publication)
    4. Godara A, Riesenburger RI, Zhang DX, Varga C, Fogaren T, Siddiqui NS, Yu A, Wang A, Mastroianni M, Dowd R, Nail TJ, McPhail ED, Kurtin PJ, Theis JD, Toskic D, Arkun K, Pilichowska M, Kryzanski J, Patel AR, Comenzo (2021). Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid, 28, 1-8. (Read full publication)
    5. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger (2021). Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. Journal of clinical neuroscience, 84, 33-37. (Read full publication)
    6. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF¿-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. Journal of clinical and translational science, 5(1), e146. (Read full publication)
    7. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski (2021). HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood advances, 5(14), 2852-2862. (Read full publication)
    8. Godara A, Siddiqui NS, Munigala S, Dhawan R, Kansagra AJ, Rapoport AP, Yared JA, Dahiya (2021). Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation. JCO oncology practice, 17(3), e355-e368. (Read full publication)
    9. Saif MW, Hachem H, Purvey S, Hamal R, Zhang L, Siddiqui NS, Godara A, Diasio R (2020). Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice. Archives of pharmacology and therapeutics, 2(1), 6-8. (Read full publication)
    10. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov D (2022). Impact of academic medical center access on outcomes in multiple myeloma. American journal of hematology, 98(1), 41-48. (Read full publication)
    11. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov (2022). A survey on the patient perspective on cure in multiple myeloma. The Lancet. Haematology, 9(10), e716-e719. (Read full publication)
    12. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin G (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. European journal of haematology, 109(5), 559-565. (Read full publication)
    13. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surgical neurology international, 13, 12. (Read full publication)
    14. Siddiqui NS, Klein A, Godara A, Buchsbaum RJ, Hughes M (2022). Predicting In-Hospital Mortality After Acute Myeloid Leukemia Therapy: Through Supervised Machine Learning Algorithms. JCO clinical cancer informatics, 6, e2200044. (Read full publication)
    15. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin G (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma, 64(7), 1-4. (Read full publication)
    16. Syeed S, Tan CJ, Godara A, Gooden K, Tang D, Slaff S, Shih YH, Ngorsuraches S, Chaiyakunapruk (2024). Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment. PharmacoEconomics, (Read full publication)
    17. Tan CJ, Kacerek D, Kampirapawong N, Godara A, Chaiyakunapruk (2025). Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review. Cancer medicine, 14(5), e70585. (Read full publication)
    18. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Kovach E, Kumar (2025). NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025. Journal of the National Comprehensive Cancer Network, 23(5), 132-140. (Read full publication)
    19. Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin G (2025). The Past, Present and Future of Myeloma Staging and Risk Prognostication. The oncologist, 30(10), (Read full publication)
    20. Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin G (2025). Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. Leukemia, 39(9), 2289-2291. (Read full publication)
    21. Galarza Fortuna GM, Peres LC, Nazarenko E, De Menezes Silva Corraes A, Hovanky V, Shune L, McGuirk JP, de Avila G, Khouri J, Dima D, Gaballa MR, Dhakal B, Forsberg PA, Godara A, Afrough A, Anderson LD Jr, Herr MM, Davis JA, Mann H, Purvey S, Clark WB, Htut MM, Beitinjaneh AM, Pereira DL, Kocoglu M, Ferreri CJ, Atrash S, Voorhees PM, Rossi AC, Richard S, Hashmi H, Patel KK, Sidana S, Lin Y, Hansen DK, Sborov D (2025). Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia. Blood advances, (Read full publication)
    22. Goldstein J, Stinson L, Sideris K, Waldron J, Mooney R, Barrell K, Godara A, Carter (2025). Hereditary transthyretin amyloidosis caused by a rare mutation. BMJ case reports, 18(7), (Read full publication)
    23. Mohyuddin GR, Chakraborty R, Berger K, Winborg R, Barnes MS, Hurtado Martinez JA, Hydren JR, Sborov D, Godara A, McClune B, Booth CM, Cliff ER (2025). Patient Preferences on Clinical Decision Making in Multiple Myeloma. JCO oncology practice, OP2500322. (Read full publication)
    24. Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K (2024). Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study. Healthcare (Basel, Switzerland), 12(16), (Read full publication)
    25. Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K (2024). Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities. Healthcare (Basel, Switzerland), 12(16), (Read full publication)

    Review

    1. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin G (2024). Multiple Myeloma in Young Patients: A Scoping Review. Clinical lymphoma, myeloma & leukemia, 24(1), 15-22. (Read full publication)

    Case Report

    1. Godara A, Migliozzi DR, Pilichowska M, Goyal N, Varga C, Gordon C (2020). Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report. Kidney medicine, 2(5), 652-656. (Read full publication)
    2. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surgical neurology international, 13, 12. (Read full publication)

    Letter

    1. Godara A, Toskic D, Albanese J, Rosenthal B, Siddiqui NS, Kugelmass A, Zhou P, Fogaren T, Varga C, Landau HJ, Comenzo R (2021). Involved free light chains <10¿mg/L with treatment predict better outcomes in systemic light-chain amyloidosis. American journal of hematology, 96(1), E20-E23. (Read full publication)
    2. Zhang Y, Godara A, Pan S, Toskic D, Mann H, Sborov D, Comenzo R, Kansagra (2022). Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. Annals of hematology, 101(9), 2119-2121. (Read full publication)
    3. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leukemia & lymphoma, 65(9), 1362-1365. (Read full publication)

    Other

    1. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-¿ antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. medRxiv, (Read full publication)